GERN

Business Context and Reporting Period

Company: Geron Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2006
Business Overview: Geron is a biopharmaceutical company developing therapeutic products for oncology targeting telomerase, pharmaceuticals activating telomerase for degenerative diseases, and cell-based therapies derived from human embryonic stem cells (hESC). The company has no approved products on the market and relies on research collaborations and licensing for revenue.

Key Financial Metrics

Liquidity: As of March 31, 2006, the company held approximately $184.2 million in cash, restricted cash, cash equivalents, and marketable securities. Management estimates these resources are sufficient to fund operations through at least December 2007.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased significantly to $583,000 from $59,000 in the prior year. This was driven by $55,000 in collaborative agreement revenues (related party reimbursements) and an increase in license fees and royalties to $528,000 (up from $59,000), largely due to a collaboration with Merck & Co., Inc.
• Operating Expenses: Total operating expenses rose to $11.4 million from $10.4 million. Research and Development (R&D) expenses increased by $2.9 million to $9.4 million, primarily due to increased personnel costs, scientific supplies, and contract manufacturing for the telomerase vaccine. General and Administrative (G&A) expenses decreased to $2.1 million from $3.9 million, excluding a one-time $2.6 million consulting expense recognized in 2005.
• Stock-Based Compensation: The company adopted SFAS 123R on January 1, 2006, resulting in the recognition of $746,000 in stock-based compensation expense for the quarter, compared to $0 in the prior year.
• Interest Income: Interest and other income increased to $1.9 million from $847,000, attributed to higher cash balances and interest rates.

Guidance, Outlook, and Risks

Outlook and Guidance:

• The company expects to recognize approximately $1.7 million in revenue for the remainder of 2006 from existing deferred revenue.
• R&D expenses are expected to increase in the coming year due to manufacturing and testing of the telomerase inhibitor GRN163L, clinical trials for the telomerase cancer vaccine, and hESC program development.
• Management anticipates G&A expenses to remain consistent with current levels.

Management Commentary:

• Clinical testing of GRN163L (telomerase inhibitor) was initiated in April 2006 for solid tumor malignancies.
• An investigator-sponsored Phase 1-2 trial for the telomerase cancer vaccine at Duke University was completed with positive immune response results and no treatment-related adverse effects.
• The company is testing six therapeutic cell types derived from hESCs in animal models, with plans to begin Phase 1-2 clinical trials for acute spinal cord injury pending successful animal studies.

Risks and Contingencies:

• Capital Needs: The company has a history of losses and will require substantial additional capital to fund operations and development. Future financing may result in dilution or require relinquishing rights to technologies.
• Regulatory Approval: No products are currently approved. Success depends on obtaining FDA and international regulatory approvals, which are uncertain, lengthy, and expensive.
• Intellectual Property: The company faces risks regarding patent validity, interference proceedings (e.g., with University of Massachusetts), and oppositions in Europe regarding hESC and telomerase technologies.
• hESC Restrictions: Political, ethical, and legal restrictions on human embryonic stem cell research could impede development and commercialization.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $184.2 million cash position against projected R&D burn rates, particularly given the initiation of new clinical trials.
• Revenue Sustainability: Assess the reliance on deferred revenue recognition ($1.7M expected for remainder of 2006) versus the need for new licensing deals to sustain long-term operations.
• Accounting Policy Impact: Review the impact of the new SFAS 123R adoption on future quarterly expenses, noting $5.9 million in unrecognized compensation cost for unvested options.
• Clinical Milestones: Monitor the progress and results of the GRN163L Phase 1-2 trials and the Duke University vaccine trial, as these are critical for future valuation.
• Patent Litigation: Track the status of patent interferences and oppositions, particularly those involving the University of Massachusetts and European patent challenges, which could threaten core IP.